跳至主要内容
临床试验/NCT05763654
NCT05763654招募中不适用

Multicenter, Long-term, Single-arm and Observational PMCF Study on the Safety of Linovera Emulsion for the Prevention of Stage 1 Pressure Ulcers, Vascular and Diabetic Foot Ulcers (PRELINEM)

B. Braun Medical SA1 个研究点 分布在 1 个国家目标入组 164 人开始时间: 2022年12月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
164
试验地点
1
主要终点
Number of adverse events

研究概览

简要总结

To assess the safety of Linovera® Emulsion in the prevention of Grade I Pressure ulcers, Vascular and Diabetic Foot Ulcers.

To assess the performance of Linovera® Emulsion for the prevention of stage 1 Pressure Ulcers, Vascular and Diabetic Foot Ulcers.

详细描述

Diverse parameters are to be used to assess the safety and efficacy of Linovera® Emulsion for the prevention of stage 1 pressure ulcer, vascular and diabetic foot ulcers.

This study is designed to implement an action within the framework of a proactive Post Market Clinical Follow up (PMCF) activity as a part of our Post Market Surveillance (PMS).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Signed informed consent
  • Patients with the possibility to participate during up 6 month follow-up.
  • At least one of these criteria:
  • Patients with medium, high or very high risk of amputation due to a vascular or diabetic foot illness.
  • Patients with medium, high or very high risk of developing a pressure ulcer due to any neuropathic foot pathology
  • Patients with medium, high or very high risk of developing a pressure ulcer following Braden Scale.

排除标准

  • Age < 18 years
  • Known allergies and/or hypersensitivity to any component of Linovera® Emulsion.
  • Any medical or psychological disorder that, in the investigator's opinion, may interfere with the patient's ability to give informed consent and comply with the study procedures.
  • Patients in the terminal stage or receiving chemotherapy.
  • Patients with more than 3 active pressure ulcers.

结局指标

主要结局

Number of adverse events

时间窗: 1 month

Number of adverse events

次要结局

  • Number of participant developing stage 1 Pressure Ulcers, Vascular and Diabetic Foot Ulcers(1 month)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验